New Approach for Enhancing Survival in Glioblastoma Patients: A Longitudinal Pilot Study on Integrative Oncology

This study evaluates the clinical outcomes of 72 patients with glioblastoma multiforme (GBM), focusing on integrative treatment (IT). The overall survival (OS) for all patients was 13.3 months, while those who received IT demonstrated significantly improved outcomes. Among the 65 patients who underwent IT, OS increased to 16.3 months. In the subgroup with high adherence (60 patients), OS extended to 25.4 months. The one-year survival rate for highly adherent patients was 59.0%, compared to 53.1% in the larger study population. In addition to survival benefits, IT contributed significantly to improved treatment tolerance. Patients receiving IT experienced fewer side effects from radiotherapy, including reduced post-radiation edema and fatigue. Blood counts remained stable, thereby permitting uninterrupted chemotherapy cycles. These findings underscore IT as a valuable addition to standard therapies, enhancing both survival and quality of life. Updated data further reinforce IT’s impact: the median survival for highly adherent patients now exceeds 55 months, with a survival rate of over 25%, far surpassing the international five-year survival rate of 3-7%. At the study’s conclusion, ten patients remained alive, highlighting IT’s potential to improve long-term outcomes in GBM treatment.